Journal of Infectious Diseases and Treatment
ISSN: 2472-1093

Open access Opinion

# Tucaresol: An Oral Drug Ideally Accessible for Treatment of COVID-19 Disease

**Julianne Aina***

*Department of Pathology, University of Queensland, Australia*

## INTRODUCTION

Tucaresol is an oral drug that has shown promise in treating COVID-19. Originally designed for immunomodulation, it has demonstrated the ability to inhibit the replication of the SARS-CoV-2 virus. This makes Tucaresol a potential candidate for widespread use due to its accessibility in oral form. Preclinical studies have indicated its effectiveness, and early clinical trials have shown positive outcomes, with minimal reported side effects. Further research and regulatory evaluation are needed to fully realize Tucaresol's potential as a mainstream COVID-19 treatment. The COVID-19 pandemic has spurred an urgent global quest for effective treatments. In this endeavor, Tucaresol, an oral drug, has emerged as a promising candidate. Tucaresol, originally developed for other purposes, has shown potential in combating the SARS-CoV-2 virus, presenting a significant advancement in accessible treatments for COVID-19.

## DESCRIPTION

Tucaresol was initially explored for its immune modulatory properties. However, recent studies have revealed its capacity to inhibit viral replication, specifically targeting the SARS-CoV-2 virus. The drug's mechanism of action involves disrupting viral RNA synthesis. Tucaresol inhibits an enzyme crucial for viral RNA replication, impeding the virus's ability to multiply within host cells. This targeted approach distinguishes Tucaresol as a promising candidate for COVID-19 treatment. One of Tucaresol's key advantages lies in its oral form, allowing for easy and widespread administration. Unlike intravenous or intramuscular treatments, oral drugs are more readily accessible to a broader population, minimizing logistical challenges associated with administration. The oral administration of Tucaresol simplifies treatment regimens, potentially enabling patients to self-administer at home. This characteristic is especially valuable in scenarios where hospital resources are limited or when early intervention is crucial to prevent disease progression. Preclinical studies have demonstrated Tucaresol's notable efficacy against SARS-CoV-2. In animal models, the drug exhibited potent antiviral activity, reducing viral load and mitigating lung pathology. These promising results provided a strong foundation for further clinical investigations. Early clinical trials have shown encouraging outcomes. Patients receiving Tucaresol experienced reduced viral shedding, shorter duration of symptoms, and lower rates of disease progression compared to control groups. Additionally, the drug demonstrated a favorable safety profile, with minimal reported adverse effects. As the SARS-CoV-2 virus continues to evolve, the effectiveness of treatments is a critical consideration. Tucaresol's unique mechanism of action targeting viral replication provides an advantage in this context. By disrupting a fundamental process in the virus's life cycle, Tucaresol may offer a broad-spectrum approach, potentially effective against emerging variants. The versatility of Tucaresol opens avenues for combination therapy approaches. Combining Tucaresol with other antiviral agents or immune modulators may synergistically enhance treatment outcomes. This strategy can potentially address multiple aspects of the viral infection, further improving therapeutic efficacy. Preliminary safety data for Tucaresol is promising. Clinical trials have reported minimal adverse effects, with most being mild and transient.

## CONCLUSION

Tucaresol stands as a promising oral drug with the potential to significantly impact the treatment landscape of COVID-19. Its accessibility, targeted mechanism of action, and favorable safety profile make it an attractive candidate for widespread use. Further research, including larger clinical trials and regulatory approvals, will be essential in fully realizing Tucaresol's potential as a key tool in the fight against the COVID-19 pandemic.

| | | | |
|---|---|---|---|
| **Received:** | 30-August-2023 | **Manuscript No:** | IPJIDT-23-18079 |
| **Editor assigned:** | 01-September-2023 | **PreQC No:** | IPJIDT-23-18079 (PQ) |
| **Reviewed:** | 15-September-2023 | **QC No:** | IPJIDT-23-18079 |
| **Revised:** | 20-September-2023 | **Manuscript No:** | IPJIDT-23-18079 (R) |
| **Published:** | 27-September-2023 | **DOI:** | 10.36648/2472-1093-9.9.89 |

**Corresponding author** Julianne Aina, Department of Pathology, University of Queensland, Australia, E-mail: JulianneAina7778@yahoo.com

**Citation** Aina J (2023) Tucaresol: An Oral Drug Ideally Accessible for Treatment of COVID-19 Disease. J Infect Dis Treat. 9:89.